Table 3 Exposure to treatment for patients treated with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab)
|  | All (n = 62) | FOLFOX + Cmab (n = 37) | XELOX + Cmab (n = 25) |
|---|---|---|---|
No. treatment cycles | Â | Â | Â |
 Median | 10 (5.5–17.5) | 10 (5–19) | 9.5 (6–14) |
Cetuximab treatment | Â | Â | Â |
 Cumulative dose (mg/m2) | 6480 (2187–12 480) | 6750 (3580–14 634) | 6397 (4302–11 198) |
 DI (mg/m2 per week) | 216 (189–247) | 223 (189–233) | 237 (179–261) |
 No. with relative DI >75 % | 52 | 28 | 24 |
Oxaliplatin | Â | Â | Â |
 Cumulative dose (mg/m2) | 992 (600–1812) | 987 (505–2021) | 1008 (661–1597) |
 DI (mg/m2 per week) | 31.4 (24–39) | 30 (28–35) | 39 (29–42) |
 No. with relative DI >75 % | 37 | 20 | 17 |
Bolus 5-FU | Â | Â | Â |
 Cumulative dose (mg/m2) |  | 4392 (1795–9928) |  |
 DI (mg/m2 per week) |  | 135 (120–175) |  |
 No. with relative DI >75 % |  | 21 |  |
5-FU Infusion | Â | Â | Â |
 Cumulative dose (mg/m2) |  | 28414 (14750–60644) |  |
 DI (mg/m2 per week) |  | 890 (803–1062) |  |
 No. with relative DI >75 % |  | 21 |  |
Capecitabine | Â | Â | Â |
 Cumulative dose (mg/m2) |  |  | 23700 (14250–38925) |
 DI (mg/m2 per week) |  |  | 878 (666–978) |
 No. with relative DI >75 % |  |  | 16 |